Twelve Weeks of Intermittent Caloric Restriction Diet Mitigates Neuroinflammation in Midlife Individuals with Multiple Sclerosis: A Pilot Study with Implications for Prevention of Alzheimer's Disease.
Alzheimer’s disease
arterial spin labeling
caloric restriction
diffusion basis spectrum imaging
multiple sclerosis
neuroinflammation
prevention
relative cerebral blood flow
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
9
5
2023
pubmed:
4
4
2023
entrez:
3
4
2023
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is a prototype neuroinflammatory disorder with increasingly recognized role for neurodegeneration. Most first-line treatments cannot prevent the progression of neurodegeneration and the resultant disability. Interventions can improve symptoms of MS and might provide insights into the underlying pathology. To investigate the effect of intermittent caloric restriction on neuroimaging markers of MS. We randomized ten participants with relapsing remitting MS to either a 12-week intermittent calorie restriction (iCR) diet (n = 5) or control (n = 5). Cortical thickness and volumes were measured through FreeSurfer, cortical perfusion was measured by arterial spin labeling and neuroinflammation through diffusion basis spectrum imaging. After 12 weeks of iCR, brain volume increased in the left superior and inferior parietal gyri (p: 0.050 and 0.049, respectively) and the banks of the superior temporal sulcus (p: 0.01). Similarly in the iCR group, cortical thickness improved in the bilateral medial orbitofrontal gyri (p: 0.04 and 0.05 in right and left, respectively), the left superior temporal gyrus (p: 0.03), and the frontal pole (p: 0.008) among others. Cerebral perfusion decreased in the bilateral fusiform gyri (p: 0.047 and 0.02 in right and left, respectively) and increased in the bilateral deep anterior white matter (p: 0.03 and 0.013 in right and left, respectively). Neuroinflammation, demonstrated through hindered and restricted water fractions (HF and RF), decreased in the left optic tract (HF p: 0.02), and the right extreme capsule (RF p: 0.007 and HF p: 0.003). These pilot data suggest therapeutic effects of iCR in improving cortical volume and thickness and mitigating neuroinflammation in midlife adults with MS.
Sections du résumé
BACKGROUND
Multiple sclerosis (MS) is a prototype neuroinflammatory disorder with increasingly recognized role for neurodegeneration. Most first-line treatments cannot prevent the progression of neurodegeneration and the resultant disability. Interventions can improve symptoms of MS and might provide insights into the underlying pathology.
OBJECTIVE
To investigate the effect of intermittent caloric restriction on neuroimaging markers of MS.
METHODS
We randomized ten participants with relapsing remitting MS to either a 12-week intermittent calorie restriction (iCR) diet (n = 5) or control (n = 5). Cortical thickness and volumes were measured through FreeSurfer, cortical perfusion was measured by arterial spin labeling and neuroinflammation through diffusion basis spectrum imaging.
RESULTS
After 12 weeks of iCR, brain volume increased in the left superior and inferior parietal gyri (p: 0.050 and 0.049, respectively) and the banks of the superior temporal sulcus (p: 0.01). Similarly in the iCR group, cortical thickness improved in the bilateral medial orbitofrontal gyri (p: 0.04 and 0.05 in right and left, respectively), the left superior temporal gyrus (p: 0.03), and the frontal pole (p: 0.008) among others. Cerebral perfusion decreased in the bilateral fusiform gyri (p: 0.047 and 0.02 in right and left, respectively) and increased in the bilateral deep anterior white matter (p: 0.03 and 0.013 in right and left, respectively). Neuroinflammation, demonstrated through hindered and restricted water fractions (HF and RF), decreased in the left optic tract (HF p: 0.02), and the right extreme capsule (RF p: 0.007 and HF p: 0.003).
CONCLUSION
These pilot data suggest therapeutic effects of iCR in improving cortical volume and thickness and mitigating neuroinflammation in midlife adults with MS.
Identifiants
pubmed: 37005885
pii: JAD221007
doi: 10.3233/JAD-221007
pmc: PMC10460547
mid: NIHMS1924105
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-273Subventions
Organisme : NIA NIH HHS
ID : RF1 AG072637
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002345
Pays : United States
Références
NMR Biomed. 2019 Feb;32(2):e4051
pubmed: 30588671
Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1768-73
pubmed: 16446459
Front Pharmacol. 2012 Apr 09;3:59
pubmed: 22509165
Curr Nutr Rep. 2017 Mar;6(1):41-48
pubmed: 28966881
Nat Rev Neurosci. 2018 Feb;19(2):63-80
pubmed: 29321682
Front Neuroinform. 2019 Feb 19;13:2
pubmed: 30837858
Ann Neurol. 2008 Sep;64(3):247-54
pubmed: 18570297
Ann Neurol. 2008 Sep;64(3):255-65
pubmed: 18661561
Cell Rep. 2018 Nov 20;25(8):2234-2243.e6
pubmed: 30463018
J Neurol. 2005 Nov;252 Suppl 5:v10-5
pubmed: 16254696
PLoS One. 2016 Mar 16;11(3):e0149685
pubmed: 26983008
Biomedicines. 2019 Dec 09;7(4):
pubmed: 31835422
Acta Neuropathol Commun. 2018 Mar 2;6(1):22
pubmed: 29499767
Neuroimage Clin. 2019;22:101767
pubmed: 30901713
AJNR Am J Neuroradiol. 2018 Jun;39(6):994-1000
pubmed: 29301779
J Neurol. 2022 Sep;269(9):4729-4741
pubmed: 35397753
Neurology. 2011 May 3;76(18):1568-74
pubmed: 21536637
J Neuroimmunol. 2017 Mar 15;304:81-85
pubmed: 27773433
Nutrients. 2021 Sep 10;13(9):
pubmed: 34579042
Cell Rep. 2016 Jun 7;15(10):2136-2146
pubmed: 27239035
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Cell Metab. 2012 Dec 5;16(6):777-88
pubmed: 23217257
J Proteomics. 2020 Apr 15;217:103645
pubmed: 31927066
Expert Opin Investig Drugs. 2017 Jun;26(6):735-739
pubmed: 28460541
Alzheimers Dement. 2012 Oct;8(5 Suppl):S78-87.e1-2
pubmed: 23021625
Cell Metab. 2018 Jun 05;27(6):1222-1235.e6
pubmed: 29874567
NMR Biomed. 2021 Jan;34(1):e4414
pubmed: 33015890
Hum Brain Mapp. 2015 May;36(5):1796-807
pubmed: 25627545
Neurology. 2004 Jan 13;62(1):60-5
pubmed: 14718698
Nutrients. 2020 Aug 30;12(9):
pubmed: 32872655
Lancet Neurol. 2012 Apr;11(4):349-60
pubmed: 22441196
J Exp Med. 2021 Feb 1;218(2):
pubmed: 33416892
Nutr J. 2015 Aug 01;14:76
pubmed: 26231781
Mult Scler Relat Disord. 2018 Jul;23:33-39
pubmed: 29753994
Neuroimage Clin. 2020;26:102248
pubmed: 32334404
JAMA Neurol. 2014 Mar;71(3):306-14
pubmed: 24445558
NMR Biomed. 2014 Jul;27(7):843-52
pubmed: 24816651
Brain. 2018 Jun 1;141(6):1665-1677
pubmed: 29741648
EBioMedicine. 2022 Aug;82:104124
pubmed: 35816900
J Magn Reson Imaging. 2008 Apr;27(4):685-91
pubmed: 18302232
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Neuroimage Clin. 2020;28:102491
pubmed: 33395982
Auto Immun Highlights. 2019 Aug 10;10(1):7
pubmed: 32257063
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 11;9(1):
pubmed: 34764215
Neurology. 2022 Apr 12;98(15):e1562-e1573
pubmed: 35173016
Neurol Neuroimmunol Neuroinflamm. 2019 Dec 23;7(2):
pubmed: 31871296
Trends Neurosci. 2020 Mar;43(3):144-154
pubmed: 32044129
Radiology. 2014 Jun;271(3):822-30
pubmed: 24555637
Neurology. 2013 Feb 5;80(6):548-52
pubmed: 23365063
Nat Neurosci. 2017 Feb;20(2):136-144
pubmed: 28092660
Front Neuroinform. 2016 Jul 27;10:30
pubmed: 27512372
Neurobiol Aging. 2020 Jun;90:84-92
pubmed: 32147244
Neuron. 2002 Jan 31;33(3):341-55
pubmed: 11832223
Ann Clin Transl Neurol. 2019 Nov;6(11):2323-2327
pubmed: 31588688
Mult Scler. 2021 Dec;27(14):2150-2158
pubmed: 33749377
Alzheimers Dement. 2015 Sep;11(9):1015-22
pubmed: 26086182
Ann N Y Acad Sci. 2001 Apr;928:316-26
pubmed: 11795523
J Leukoc Biol. 2008 Oct;84(4):940-8
pubmed: 18678605